医学
心脏病学
四分位间距
内科学
室性心动过速
植入式心律转复除颤器
临床终点
危险系数
多中心试验
随机对照试验
休克(循环)
烧蚀
心动过速
导管消融
置信区间
多中心研究
作者
Paolo Emilio Della Bella,Francesca Baratto,Pasquale Vergara,Patrizia Bertocchi,Matteo Santamaria,Pasquale Notarstefano,Leonardo Calò,Daniela Orsida,Luca Tomasi,Marcello Piacenti,Stefano Sangiorgio,Francesco Pentimalli,Etienne J. Pruvot,João de Sousa,Frédéric Sacher,Massimo Vito Tritto,Luca Rebellato,Thomas Deneke,Salvo Andrea Romano,Martina Nesti
出处
期刊:Circulation
[Lippincott Williams & Wilkins]
日期:2022-04-03
卷期号:145 (25): 1829-1838
被引量:216
标识
DOI:10.1161/circulationaha.122.059598
摘要
Background: Optimal timing for catheter ablation of ventricular tachycardia is an important unresolved issue. There are no randomized trials evaluating the benefit of ablation after the first implantable cardioverter defibrillator (ICD) shock. Methods: We conducted a 2-phase, prospective, multicenter, randomized clinical trial. Patients with ischemic or nonischemic dilated cardiomyopathy and primary or secondary prevention indication for ICD were enrolled in an initial observational phase until first appropriate shock (phase A). After reconsenting, patients were randomly assigned 1:1 in phase B to immediate ablation (within 2 months from shock delivery) or continuation of standard therapy. The primary end point was a composite of death from any cause or hospitalization for worsening heart failure. Amiodarone intake was not allowed except for documented atrial tachyarrhythmias. On July 23, 2021, phase B of the trial was interrupted as a result of the first interim analysis on the basis of the Bayesian adaptive design. Results: Of the 517 patients enrolled in phase A, 154 (30%) had ventricular tachycardia, 56 (11%) received an appropriate shock over a median follow-up of 2.4 years (interquartile range, 1.4–4.4), and 47 of 56 (84%) agreed to participate in phase B. After 24.2 (8.5–24.4) months, the primary end point occurred in 1 of 23 (4%) patients in the ablation group and 10 of 24 (42%) patients in the control group (hazard ratio, 0.11 [95% CI, 0.01–0.85]; P =0.034). The results met the prespecified termination criterion of >99% Bayesian posterior probability of superiority of treatment over standard therapy. No deaths were observed in the ablation group versus 8 deaths (33%) in the control group ( P =0.004); there was 1 worsening heart failure hospitalization in the ablation group (4%) versus 4 in the control group (17%; P =0.159). ICD shocks were less frequent in the ablation group (9%) than in the control group (42%; P =0.039). Conclusions: Ventricular tachycardia ablation after first appropriate shock was associated with a reduced risk of the combined death or worsening heart failure hospitalization end point, lower mortality, and fewer ICD shocks. These findings provide support for considering ventricular tachycardia ablation after the first ICD shock. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01547208.
科研通智能强力驱动
Strongly Powered by AbleSci AI